NeoGenomics (NASDAQ:NEO) COO Warren Stone Sells 22,128 Shares

NeoGenomics, Inc. (NASDAQ:NEO) COO Warren Stone sold 22,128 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total transaction of $276,600.00. Following the completion of the transaction, the chief operating officer owned 121,631 shares in the company, valued at $1,520,387.50. This represents a 15.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

NeoGenomics Trading Up 0.4%

NeoGenomics stock traded up $0.05 during trading hours on Wednesday, reaching $12.69. The stock had a trading volume of 1,714,208 shares, compared to its average volume of 1,671,731. The company has a fifty day simple moving average of $11.98 and a 200-day simple moving average of $9.36. NeoGenomics, Inc. has a 52 week low of $4.72 and a 52 week high of $15.32. The stock has a market cap of $1.64 billion, a PE ratio of -14.42 and a beta of 1.58. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.91 and a quick ratio of 3.62.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. The company had revenue of $187.80 million for the quarter, compared to the consensus estimate of $183.85 million. NeoGenomics had a negative return on equity of 3.36% and a negative net margin of 16.00%.NeoGenomics’s revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.05 EPS. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. Analysts forecast that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Institutional Investors Weigh In On NeoGenomics

Several hedge funds have recently added to or reduced their stakes in the stock. Aster Capital Management DIFC Ltd increased its holdings in shares of NeoGenomics by 42.5% during the third quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 997 shares in the last quarter. Headlands Technologies LLC purchased a new stake in NeoGenomics during the 2nd quarter valued at about $32,000. GAMMA Investing LLC increased its stake in NeoGenomics by 68.2% during the 4th quarter. GAMMA Investing LLC now owns 3,602 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 1,460 shares in the last quarter. Capstone Financial Advisors Inc. purchased a new position in NeoGenomics in the second quarter worth about $73,000. Finally, Captrust Financial Advisors bought a new position in shares of NeoGenomics in the second quarter worth approximately $75,000. 98.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. TD Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a research note on Wednesday, January 7th. Zacks Research raised NeoGenomics from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeoGenomics in a report on Monday, December 29th. Needham & Company LLC restated a “buy” rating and issued a $14.00 target price on shares of NeoGenomics in a research note on Monday, January 12th. Finally, Leerink Partners set a $14.00 price target on NeoGenomics in a research note on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $12.00.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.